tbuckley/cabot-search huggingface dataset:
Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease
Authors: Matthieu Turpin, Christelle Chantalat-Auger, Florence Parent, Françoise Driss, François Lionnet, Anoosha Habibi, Bernard Maître, Alice Huertas, Xavier Jaïs, Jason Weatherald, David Montani, Olivier Sitbon, Gérald Simonneau, Fréderic Galactéros, Marc Humbert, Pablo Bartolucci, Laurent Savale
Journal: European Respiratory Journal (2018)

The long-term effects of chronic blood exchange transfusions (BETs) on pre-capillary pulmonary hypertension complicating sickle cell disease (SCD) are unknown. 13 homozygous SS SCD patients suffering from pre-capillary pulmonary hypertension and treated by chronic BETs were evaluated retrospectively. Assessments included haemodynamics, New York Heart Association Functional Class (NYHA FC), 6-min walk distance (6MWD) and blood tests. Before initiating BETs, all patients were NYHA FC III or IV, median (range) 6MWD was 223 (0–501) m and median (range) pulmonary vascular resistance (PVR) was 3.7 (2–12.5) Wood Units. After a median number of 4 BET sessions, all patients had improved to NYHA FC II or III. Significant improvements in haemodynamics were observed, including a decrease in PVR (p=0.01). There was a trend to higher 6MWD (p=0.09). Median (range) follow-up time after initiation of BETs was 25 (6–53) months. During this period, two patients decided to stop BETs. One of them died from acute right heart failure and the other experienced worsening pulmonary hypertension. Two other patients died during follow-up at 25 and 54 months after BET initiation. Chronic BETs may be a potential therapeutic option in pre-capillary pulmonary hypertension complicating SCD, leading to significant clinical and haemodynamic improvements. These data must be confirmed in a prospective study.
Three cases of venous thromboembolism in advanced cancer patients
Authors: Keigo Komine, Masanobu Takahashi, Sakura Hiraide, Sho Umegaki, Yoshifumi Kawamura, Hideharu Yamada, Akira Okita, Sonoko Chikamatsu, Yuki Kasahara, Yoshinari Okada, Hiroo Imai, Ken Saijo, Masahiro Takahashi, Hidekazu Shirota, Chikashi Ishioka
Journal: Annals of Oncology (2018)
GW29-e1007 Metabolomics reveals metabolite changes of patients with pulmonary arterial hypertension in China
Authors: Fei Luo, Chenyang Chen, Panyun Wu, Yiyuan Huang, Gaoxing Shi, Shenglan Chen, Jingyuan Chen, Xinqun Hu, Shenghua Zhou, Zhenfei Fang
Journal: Journal of the American College of Cardiology (2018)
Treating oxidative stress in heart failure: past, present and future
Authors: Atze van der Pol, Wiek H. van Gilst, Adriaan A. Voors, Peter van der Meer
Journal: European Journal of Heart Failure (2018)

Advances in cardiovascular research have identified oxidative stress as an important pathophysiological pathway in the development and progression of heart failure. Oxidative stress is defined as the imbalance between the production of reactive oxygen species (ROS) and the endogenous antioxidant defence system. Under physiological conditions, small quantities of ROS are produced intracellularly, which function in cell signalling, and can be readily reduced by the antioxidant defence system. However, under pathophysiological conditions, the production of ROS exceeds the buffering capacity of the antioxidant defence system, resulting in cell damage and death. Over the last decades several studies have tried to target oxidative stress with the aim to improve outcome in patients with heart failure, with very limited success. The reasons as to why these studies failed to demonstrate any beneficial effects remain unclear. However, one plausible explanation might be that currently employed strategies, which target oxidative stress by exogenous inhibition of ROS production or supplementation of exogenous antioxidants, are not effective enough, while bolstering the endogenous antioxidant capacity might be a far more potent avenue for therapeutic intervention. In this review, we provide an overview of oxidative stress in the pathophysiology of heart failure and the strategies utilized to date to target this pathway. We provide novel insights into modulation of endogenous antioxidants, which may lead to novel therapeutic strategies to improve outcome in patients with heart failure.
Efficacy of anlotinib in advanced soft tissue sarcoma by prior lines of therapy, age and dose modification
Authors: Y. Yao, Y. Chi, Z. Fang, S. Wang, G. Huang, Q. Cai, G. Shang, G. Wang, G. Qu, Q. Wu, Y. Jiang, J. Song, J. Chen, X. Zhu, Z. Cai, C. Bai, Y. Lu, Z. Yu, J. Shen, J. Cai
Journal: Annals of Oncology (2018)
Outcomes of Patients With Mediastinal Radiation-Associated Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Authors: Eoin Donnellan, Amar Krishnaswamy, Erika Hutt-Centeno, Douglas R. Johnston, Jose Aguilera, Samir R. Kapadia, Stephanie Mick, Lars G. Svensson, Brian P. Griffin, Milind Y. Desai
Journal: Circulation (2018)
GW29-e0474 Chronic ethanol increases Calcium/Calmoldulin-Dependent protein kinaseIIδ gene expression and decreases monoamine oxidase amount in Rats' heart muscles: Rescue effect of Gingiber Officinale (ginger) extract
Authors: Alireza Shirpoor, Elaheh Heshmati, Mohammad Alizadeh
Journal: Journal of the American College of Cardiology (2018)
Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial
Authors: Michael Doherty, Wendy Jenkins, Helen Richardson, Aliya Sarmanova, Abhishek Abhishek, Deborah Ashton, Christine Barclay, Sally Doherty, Lelia Duley, Rachael Hatton, Frances Rees, Matthew Stevenson, Weiya Zhang
Journal: The Lancet (2018)

BackgroundIn the UK, gout management is suboptimum, with only 40% of patients receiving urate-lowering therapy, usually without titration to achieve a target serum urate concentration. Nurses successfully manage many diseases in primary care. We compared nurse-led gout care to usual care led by general practitioners (GPs) for people in the community.MethodsResearch nurses were trained in best practice management of gout, including providing individualised information and engaging patients in shared decision making. Adults who had experienced a gout flare in the previous 12 months were randomly assigned 1:1 to receive nurse-led care or continue with GP-led usual care. We assessed patients at baseline and after 1 and 2 years. The primary outcome was the percentage of participants who achieved serum urate concentrations less than 360 μmol/L (6 mg/dL) at 2 years. Secondary outcomes were flare frequency in year 2, presence of tophi, quality of life, and cost per quality-adjusted life-year (QALY) gained. Risk ratios (RRs) and 95% CIs were calculated based on intention to treat with multiple imputation. This study is registered with www.ClinicalTrials.gov, number NCT01477346.Findings517 patients were enrolled, of whom 255 were assigned nurse-led care and 262 usual care. Nurse-led care was associated with high uptake of and adherence to urate-lowering therapy. More patients receiving nurse-led care had serum urate concentrations less than 360 μmol/L at 2 years than those receiving usual care (95% vs 30%, RR 3·18, 95% CI 2·42–4·18, p<0·0001). At 2 years all secondary outcomes favoured the nurse-led group. The cost per QALY gained for the nurse-led intervention was £5066 at 2 years.InterpretationNurse-led gout care is efficacious and cost-effective compared with usual care. Our findings illustrate the benefits of educating and engaging patients in gout management and reaffirm the importance of a treat-to-target urate-lowering treatment strategy to improve patient-centred outcomes.FundingArthritis Research UK.
P3.12-06 SLFN11 Expression and Efficacy of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study
Authors: T. Owonikoko, S. Dahlberg, G. Sica, J. Poirier, L. Byers, C. Rudin, I. Wistuba, S. Ramalingam
Journal: Journal of Thoracic Oncology (2018)
Whole-exome cfDNA profiling captures the mutational signatures of metastatic breast cancer for monitoring disease evolution
Authors: R.K. Hastings, M.R. Openshaw, M. Vazquez, D. Fernandez-Garcia, D. Guttery, K. Page, B. Toghill, A. Thomas, S. Ahmed, R.A. Toledo, J.A. Shaw
Journal: Annals of Oncology (2018)
Metformin Targets Mitochondrial Electron Transport to Reduce Air-Pollution-Induced Thrombosis
Authors: Saul Soberanes, Alexander V. Misharin, Amit Jairaman, Luisa Morales-Nebreda, Alexandra C. McQuattie-Pimentel, Takugo Cho, Robert B. Hamanaka, Angelo Y. Meliton, Paul A. Reyfman, James M. Walter, Ching-I Chen, Monica Chi, Stephen Chiu, Francisco J. Gonzalez-Gonzalez, Matthew Antalek, Hiam Abdala-Valencia, Sergio E. Chiarella, Kaitlyn A. Sun, Parker S. Woods, Andrew J. Ghio, Manu Jain, Harris Perlman, Karen M. Ridge, Richard I. Morimoto, Jacob I. Sznajder, William E. Balch, Sangeeta M. Bhorade, Ankit Bharat, Murali Prakriya, Navdeep S. Chandel, Gökhan M. Mutlu, G.R. Scott Budinger
Journal: Cell Metabolism (2018)
P3.11-02 Lung Cancer Screening in a High Incidence Population: Results of Low-Dose CT Screenings in a Northern Kentucky Community Healthcare System
Authors: R. Calhoun, G. Turner, G. Schmitt, M. Gieske, E. Krasik, V. Williams, S. Browne, M. Lockwood, E. Burns, A. Snow
Journal: Journal of Thoracic Oncology (2018)
Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial
Authors: M. Abdelshafy, Y. El Dakdouki, L. Verlingue, A. Hollebecque, L. Lacroix, S. Postel-Vinay, A. Varga, R. Balheda, J.-M. Michot, A. Marabelle, E. Rouleau, E. Solary, T. de Baere, E. Angevin, V. Ribrag, S. Michiels, F. André, J.-Y. Scoazec, J.-C. Soria, C. Massard
Journal: Annals of Oncology (2018)
GW29-e0695 Diagnostic Accuracy of High-sensitivity Cardiac Troponin I for Myocardial Infarction in ICU Patients Except Cardiovascular Department
Authors: Hongyuan Bai, Haiquan Li, Limin Chai, Jie Deng, Jin Wei, Qiangsun Zheng
Journal: Journal of the American College of Cardiology (2018)
KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
Authors: D. Rodriguez Abreu, M.C. Garassino, E. Esteban, G. Speranza, E. Felip, M. Domine, M.J. Hochmair, S.F. Powell, S.Y.-S. Cheng, H. Bischoff, N. Peled, R. Hui, M. Reck, E.B. Garon, M. Boyer, F. Grossi, R. Jennens, J. Yang, M.C. Pietanza, S.M. Gadgeel
Journal: Annals of Oncology (2018)
Association Between Psoriasis and Sexual and Erectile Dysfunction in Epidemiologic Studies
Authors: Alejandro Molina-Leyva, Luis Salvador-Rodriguez, Antonio Martinez-Lopez, Jose Carlos Ruiz-Carrascosa, Salvador Arias-Santiago
Journal: JAMA Dermatology (2018)

Sexual health is a major aspect of life. Increasing scientific evidence shows a potential association between psoriasis and sexual dysfunction (SD) and erectile dysfunction (ED).To evaluate the available scientific evidence regarding epidemiologic associations and treatment outcomes between psoriasis and SD and ED.Information sources were MEDLINE and Embase databases, using the Scopus search engine. The search was performed on August 25, 2017. Search terms were psoriasis and sexual or sexual dysfunction, and the search was limited to epidemiologic studies published in English answering any of the 4 research questions. Quality was assessed according to the Centre for Evidence-Based Medicine.Twenty-eight studies representing 52 520 cases of psoriasis and 1 806 022 controls were included for review. Of the 28 studies, 19 were cross-sectional, 3 were clinical trials, 3 were quasi-experimental, 2 were population-based cohort, and 1 was population-based case-control. Prevalence of SD and ED ranged from 40.0% to 55.6% and 34.2% to 81.1%, respectively. Two of 2 studies observed an association between psoriasis and SD after adjusting for physical and psychological comorbidities. Five of 8 studies observed an independent association between ED and psoriasis. Among patients with psoriasis, the features that showed the strongest association with SD were anxiety and depression (5 of 5 studies), psoriatic arthritis (3 of 4 studies), and genital psoriasis (5 of 7 studies). Regarding ED, anxiety and depression (2 of 2 studies) and increasing age (3 of 3 studies) showed the strongest association. All 3 clinical trials using biologic drugs showed an improvement in SD compared with placebo.Patients with psoriasis have physical and psychological comorbidities that have been associated with a higher risk of SD. In addition, psoriasis may play a role in its development. The presence of anxiety, depression, psoriatic arthritis, genital lesions, and increasing age should raise the awareness of SD. Biologic drugs have demonstrated the improvement of SD in patients with psoriasis.
Impaired osteocyte maturation in the pathogenesis of renal osteodystrophy
Authors: Renata C. Pereira, Isidro B. Salusky, Paul Roschger, Klaus Klaushofer, Ora Yadin, Earl G. Freymiller, Richard Bowen, Anne M. Delany, Nadja Fratzl-Zelman, Katherine Wesseling-Perry
Journal: Kidney International (2018)
Mixed-effects association of single cells identifies an expanded effector CD4<sup>+</sup>T cell subset in rheumatoid arthritis
Authors: Chamith Y. Fonseka, Deepak A. Rao, Nikola C. Teslovich, Ilya Korsunsky, Susan K. Hannes, Kamil Slowikowski, Michael F. Gurish, Laura T. Donlin, James A. Lederer, Michael E. Weinblatt, Elena M. Massarotti, Jonathan S. Coblyn, Simon M. Helfgott, Derrick J. Todd, Vivian P. Bykerk, Elizabeth W. Karlson, Joerg Ermann, Yvonne C. Lee, Michael B. Brenner, Soumya Raychaudhuri
Journal: Science Translational Medicine (2018)

High-dimensional single-cell analyses have improved the ability to resolve complex mixtures of cells from human disease samples; however, identifying disease-associated cell types or cell states in patient samples remains challenging because of technical and interindividual variation. Here, we present mixed-effects modeling of associations of single cells (MASC), a reverse single-cell association strategy for testing whether case-control status influences the membership of single cells in any of multiple cellular subsets while accounting for technical confounders and biological variation. Applying MASC to mass cytometry analyses of CD4+ T cells from the blood of rheumatoid arthritis (RA) patients and controls revealed a significantly expanded population of CD4+ T cells, identified as CD27- HLA-DR+ effector memory cells, in RA patients (odds ratio, 1.7; P = 1.1 × 10-3). The frequency of CD27- HLA-DR+ cells was similarly elevated in blood samples from a second RA patient cohort, and CD27- HLA-DR+ cell frequency decreased in RA patients who responded to immunosuppressive therapy. Mass cytometry and flow cytometry analyses indicated that CD27- HLA-DR+ cells were associated with RA (meta-analysis P = 2.3 × 10-4). Compared to peripheral blood, synovial fluid and synovial tissue samples from RA patients contained about fivefold higher frequencies of CD27- HLA-DR+ cells, which comprised ~10% of synovial CD4+ T cells. CD27- HLA-DR+ cells expressed a distinctive effector memory transcriptomic program with T helper 1 (TH1)- and cytotoxicity-associated features and produced abundant interferon-γ (IFN-γ) and granzyme A protein upon stimulation. We propose that MASC is a broadly applicable method to identify disease-associated cell populations in high-dimensional single-cell data.
GW29-e0593 Association of Depression and Unhealthy Lifestyle Behaviors in Chinese Patients with Acute Coronary Syndromes
Authors: Yidan Zhu, Xin Yu, Yangfeng Wu, Chuan Shi, Aihua Zhang, Ronghuan Jiang, Shenshen Li, Guifang Guo, Runlin Gao, James A. Blumenthal
Journal: Journal of the American College of Cardiology (2018)
Abstract 18907: Antithrombotic Therapy After TAVR: An Updated Meta-analysis of Single versus Dual-Antiplatelet Therapy of Randomized and Propensity-Matched Studies
Authors: Gilson C Fernandes, Guilherme Nasi, Manuel Rivera, Rhanderson Cardoso, Eduardo de Marchena, Mauricio G Cohen, Carlos E Alfonso
Journal: Circulation (2017)

Introduction: Since the initial trials, dual-antiplatelet therapy (DAPT) for 6 months is the recommended antiplatelet regimen after Transcatheter Aortic Valve Replacement (TAVR). The goal of this m...
Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Authors: Scott T. Tagawa, Emmanuel S. Antonarakis, Ada Gjyrezi, Giuseppe Galletti, Seaho Kim, Daniel Worroll, John Stewart, Atef Zaher, Ted P. Szatrowski, Karla V. Ballman, Katsuhiro Kita, Shinsuke Tasaki, Yang Bai, Luigi Portella, Brian J. Kirby, Fred Saad, Mario A. Eisenberger, David M. Nanus, Paraskevi Giannakakou
Journal: Clinical Cancer Research (2018)

Biomarkers aiding treatment optimization in metastatic castration-resistant prostate cancer (mCRPC) are scarce. The presence or absence of androgen receptor (AR) splice variants, AR-V7 and AR
Cannabis based drugs: GPs will have to manage patients’ expectations, says expert
Authors: Gareth Iacobucci
Journal: BMJ (2018)

GPs could be inundated with requests for cannabis derived medicines next month without the resources to properly advise patients, an expert has warned.

Ian Hamilton, a lecturer in addiction at the University of York, has welcomed the announcement by the UK home secretary, Sajid Javid, that specialist doctors in England, Wales, and Scotland will be able to prescribe cannabis based products for medicinal use from 1 November.1 But he warned that patients could face lengthy waits for treatment because of the “considerable” demand that the move could create.

“It potentially gives a lot of patients false hope that this is going to be a relatively smooth and easy process. It’s going to be quite protracted: you’ve got to see your GP, and they have to make a referral to a specialist. Whether you’re in primary or secondary care, the last thing you want is additional demand, but that is what it’s going …
GW29-e1534 Heart failure status evaluated through different ways and risk of ischemic stroke in atrial fibrillation patients with coronary stenting
Authors: Ge Wang, Li Zhao, Boyang Zhang, Nannan Wang, Pengfei Liu, Feng Wang, Haihong Tang, Can Hua, Haifeng Yuan, Xiufeng Xie, Yubin Wang, Tianchang Li
Journal: Journal of the American College of Cardiology (2018)
Antibiotic resistance in Palestine: an emerging part of a larger crisis
Authors: Rupa Kanapathipillai, Nada Malou, Kate Baldwin, Pascale Marty, Camille Rodaix, Clair Mills, Patrick Herard, Malika Saim
Journal: BMJ (2018)

Supporting previous letters published in The BMJ about the violent response of Israeli forces to Palestinian protestors in Gaza,123 Medecins Sans Frontieres (MSF) has received 2228 trauma patients from April to September. The total number of injured has now reached 20 833, with 191 deaths.4 About 90% of Palestinian patients seeking care from MSF have had lower limb injuries from gunshot wounds, …
Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data
Authors: Michael F Gensheimer, A Solomon Henry, Douglas J Wood, Trevor J Hastie, Sonya Aggarwal, Sara A Dudley, Pooja Pradhan, Imon Banerjee, Eunpi Cho, Kavitha Ramchandran, Erqi Pollom, Albert C Koong, Daniel L Rubin, Daniel T Chang
Journal: JNCI Journal of the National Cancer Institute (2018)

Oncologists use patients' life expectancy to guide decisions and may benefit from a tool that accurately predicts prognosis. Existing prognostic models generally use only a few predictor variables. We used an electronic medical record dataset to train a prognostic model for patients with metastatic cancer.
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600–Mutant Stage III Melanoma
Authors: Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Thierry Lesimple, Ruth Plummer, Kohinoor Dasgupta, Tomas Haas, Mark Shilkrut, Eduard Gasal, Richard Kefford, John M. Kirkwood, Georgina V. Long
Journal: Journal of Clinical Oncology (2018)

Purpose Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio [HR], 0.47; P &lt; .001) in patients with resected BRAF V600–mutant stage III melanoma (BRF115532; COMBI-AD; ClinicalTrials.gov identifier: NCT01682083). We present an updated RFS analysis on the basis of extended study follow-up and a cure-rate model analysis to estimate the fraction of patients expected to remain relapse free long term. Methods In this phase III trial, patients with resected BRAF V600–mutant stage III melanoma were randomly assigned to 12 months of adjuvant dabrafenib plus trametinib versus placebo. We report updated RFS (primary end point) and distant metastasis–free survival. RFS was also analyzed by subgroups defined by baseline disease stage (American Joint Committee on Cancer 7th and 8th editions), nodal metastatic burden, and ulceration status. The fraction of patients who remained relapse free long term was estimated using a Weibull mixture cure-rate model. Results At median follow-up of 44 months (dabrafenib plus trametinib) and 42 months (placebo), 3- and 4-year RFS rates were 59% (95% CI, 55% to 64%) and 54% (95% CI, 49% to 59%) in the dabrafenib plus trametinib arm and 40% (95% CI, 35% to 45%) and 38% (95% CI, 34% to 44%) in the placebo arm, respectively (HR, 0.49; 95% CI, 0.40 to 0.59). Distant metastasis–free survival also favored dabrafenib plus trametinib (HR, 0.53; 95% CI, 0.42 to 0.67). The estimated cure rate was 54% (95% CI, 49% to 59%) in the dabrafenib plus trametinib arm compared with 37% (95% CI, 32% to 42%) in the placebo arm. Subgroup analysis of RFS demonstrated similar treatment benefit regardless of baseline factors, including disease stage, nodal metastatic burden, and ulceration. Conclusion Longer follow-up confirmed RFS benefit with dabrafenib plus trametinib. Subgroup analysis suggested that dabrafenib plus trametinib benefited patients regardless of baseline factors.
Abstract 19599: Continuous versus 3 Weeks Intermittent ECG Monitoring for Detection of Subclinical Atrial Fibrillation in High-Risk Patients
Authors: Tine J Philippsen, Lene S Christensen, Michael G Hansen, Axel Brandes
Journal: Circulation (2016)

Background: Atrial fibrillation (AF) often occurs in a subclinical form, which makes it difficult to detect. The effect of continuous versus intermittent rhythm monitoring to detect subclinical AF ...
AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)
Authors: M. Español Rego, V. Alonso, J. Aparicio, E. Elez Fernandez, P. Escudero, C. Fernández-Martos, N. Rodríguez, A. Ruiz Casado, J. Cid, R. Cabezón, M. Lozano, A. Ginés, L. Bianchi, J. Garcia-Corbacho, X. García de Albéniz, J. Maurel, D. Benitez Ribas
Journal: Annals of Oncology (2018)
Glycan targeted polymeric antibiotic prodrugs for alveolar macrophage infections
Authors: Jasmin Chen, Fang-Yi Su, Debobrato Das, Selvi Srinivasan, Hye-Nam Son, Brian Lee, Frank Radella, Dale Whittington, Taylor Monroe-Jones, T. Eoin West, Anthony J. Convertine, Shawn J. Skerrett, Patrick S. Stayton, Daniel M. Ratner
Journal: Biomaterials (2018)
P3.16-37 Comparison of Long-Term Outcomes Between VATS and Open Lobectomies for Stage I NSCLC: Propensity Score-Matching Analysis
Authors: R. Oda, K. Okuda, T. Watanabe, T. Sakane, T. Tatematsu, K. Yokota, H. Haneda, R. Nakanishi
Journal: Journal of Thoracic Oncology (2018)